Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region

Karuna, Shelly; Gallardo-Cartagena, Jorge A; Theodore, Deborah; Hunidzarira, Portia; Montenegro-Idrogo, Juan José; Hu, Jiani; Jones, Megan; Kim, V.; Grecca, Robert De La; Trahey, Meg; Karg, Carissa; Takalani, Azwi; Polakowski, Laura; Hütter, Julia; Miner, Maurine D.; Erdmann, Nathan; Goepfert, Paul; Maboa, Rebone; Corey, Lawrence; Gill, Katherine; Li, Shuying Sue

doi:10.7189/jogh.13.06020

Cited by 11 publications

(8 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies were conducted from early 2020 to mid-2023 in twenty-eight different countries across Europe, the Americas, Africa and Asia ( Table 2 and Table 3 ). Forty-one studies were sourced from peer-review journals [ 8 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ]. Four studies were pre-print and were awaiting peer review at the time of writing [ 70 , 71 , 72 , 73 ].…”

Section: Resultsmentioning

confidence: 99%

“…Twenty-eight studies included only participants with a positive reverse transcription polymerase chain reaction test (RT-PCR) for SARS-CoV-2 [ 32 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 57 , 58 , 60 , 61 , 62 , 65 , 67 , 68 , 69 , 71 , 72 , 73 ]. Seven studies included participants who tested positive via an unspecified diagnostic method [ 30 , 33 , 56 , 59 , 64 , 66 , 70 ]. Two database studies included participants with an ICD-10 code for confirmed COVID-19 in their electronic health record (EHR) [ 8 , 60 ].…”

Section: Resultsmentioning

confidence: 99%

“…The studies also varied in their clinical settings and ascertainment of gastrointestinal symptoms. Fourteen studies were conducted on patients who were hospitalised with COVID-19, discharged and followed up in the community [ 33 , 34 , 35 , 41 , 42 , 43 , 44 , 45 , 57 , 60 , 62 , 63 , 67 , 71 ], twenty-one studies involved both hospitalised and community-managed cases [ 8 , 30 , 32 , 36 , 37 , 40 , 46 , 47 , 48 , 49 , 50 , 55 , 59 , 61 , 64 , 65 , 66 , 68 , 69 , 70 , 72 ], seven studies involved community cases that did not require hospital admission [ 38 , 39 , 51 , 52 , 53 , 56 , 58 ] and three studies did not specify the setting of recruitment [ 31 , 54 , 73 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection

Hawkings

Vaselli

Charalampopoulos

et al. 2023

Viruses

View full text Add to dashboard Cite

It is known that SARS-CoV-2 infection can result in gastrointestinal symptoms. For some, these symptoms may persist beyond acute infection, in what is known as ‘post-COVID syndrome’. We conducted a systematic review to examine the prevalence of persistent gastrointestinal symptoms and the incidence of new gastrointestinal illnesses following acute SARS-CoV-2 infection. We searched the scientific literature using MedLine, SCOPUS, Europe PubMed Central and medRxiv from December 2019 to July 2023. Two reviewers independently identified 45 eligible articles, which followed participants for various gastrointestinal outcomes after acute SARS-CoV-2 infection. The study quality was assessed using the Joanna Briggs Institute Critical Appraisal Tools. The weighted pooled prevalence for persistent gastrointestinal symptoms of any nature and duration was 10.8% compared with 4.9% in healthy controls. For seven studies at low risk of methodological bias, the symptom prevalence ranged from 0.2% to 24.1%, with a median follow-up time of 18 weeks. We also identified a higher risk for future illnesses such as irritable bowel syndrome, dyspepsia, hepatic and biliary disease, liver disease and autoimmune-mediated illnesses such as inflammatory bowel disease and coeliac disease in historically SARS-CoV-2-exposed individuals. Our review has shown that, from a limited pool of mostly low-quality studies, previous SARS-CoV-2 exposure may be associated with ongoing gastrointestinal symptoms and the development of functional gastrointestinal illness. Furthermore, we show the need for high-quality research to better understand the SARS-CoV-2 association with gastrointestinal illness, particularly as population exposure to enteric infections returns to pre-COVID-19-restriction levels.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection

Hawkings

Vaselli

Charalampopoulos

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Our study demonstrated a faster resolution of COVID-19 symptoms among participants enrolled in the VCO group. Early diminishment of symptoms is beneficial, especially since studies have shown that COVID-19 symptoms can last from 20 days ( 27 ) to 83 days ( 28 ) , which can greatly affect an individual’s quality of life. The anti-inflammatory properties of VCO and its ability to modulate the immune system may have been the main reason behind the early resolution of the participants’ symptoms, especially when fever, which is one of the main symptoms of COVID-19, is a clinical hallmark of inflammation ( 10 ) .…”

Section: Discussionmentioning

confidence: 99%

Virgin coconut oil (VCO) supplementation relieves symptoms and inflammation among COVID-19 positive adults: a single-blind randomized trial

Angeles-Agdeppa,

Nacis,

Dayrit

et al. 2024

J Nutr Sci

View full text Add to dashboard Cite

A clinical study conducted in 2020 showed that virgin coconut oil (VCO) has been found effective in the rapid relief of COVID-19 symptoms and normalization of the C-reactive protein (CRP) concentration among probable and suspected cases of COVID-19. This present study aimed to validate those results and to evaluate the effects of VCO among COVID-19 patients through a 28-day randomized, single-blind trial conducted among 76 SARS-CoV-2 RT-PCR (reverse transcription-polymerase chain report)-confirmed adults, with VCO given as a COVID-19 adjunct therapy. The results showed that VCO recipients were free from symptoms and had normal CRP concentrations by day 14. In comparison, participants in the control group reported relief from signs and symptoms on day 23, with normal CRP concentrations on day 25. This second study bolsters the use of VCO as an effective adjunct therapy for COVID-19-positive patients showing mild-to-moderate symptoms.

show abstract

“…(13) Similarly, long COVID is reported by persons of all genders, race/ethnicities, and those with and without pre-existing comorbidities. (13,14) Hence, it is essential that research both identifies and characterizes the main clinical and epidemiological features associated with long COVID, including potential targets for intervention.…”

Section: Introductionmentioning

confidence: 99%

Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Wentz,

Ni,

Yenokyan

et al. 2024

Preprint

View full text Add to dashboard Cite

PurposeCOVID-19 disease continues to affect millions of individuals worldwide, both in the short and long term. The post-acute complications of SARS-CoV-2 infection, referred to as long COVID, result in diverse symptoms affecting multiple organ systems. Little is known regarding how the symptoms associated with long COVID progress and resolve over time. The Johns Hopkins COVID Long Study aims to prospectively examine the short- and long-term consequences of COVID-19 disease in individuals both with and without a history of SARS-CoV-2 infection using self-reported data collected in an online survey.ParticipantsSixteen thousand, seven hundred sixty-four adults with a history of SARS-CoV-2 infection and 799 adults without a history of SARS-CoV-2 infection who completed an online baseline survey.Findings to dateThis cohort profile describes the baseline characteristics of the Johns Hopkins COVID Long Study. Among 16,764 participants with a history of SARS-CoV-2 infection and defined long COVID status, 75% reported a good or excellent health status prior to infection, 99% reported experiencing at least one COVID-19 symptom during the acute phase of infection, 9.9% reported a hospitalization, and 63% were defined as having long COVID using the WHO definition.Future plansAnalysis of longitudinal data will be used to investigate the progression and resolution of long COVID symptoms over time.

show abstract

Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region

Cited by 11 publications

References 47 publications

A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection

A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection

Virgin coconut oil (VCO) supplementation relieves symptoms and inflammation among COVID-19 positive adults: a single-blind randomized trial

Cohort profile: the Johns Hopkins COVID Long Study (JHCLS), a United States Nationwide Prospective Cohort Study

Contact Info

Product

Resources

About